Page 2 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Sartorius Stedim Biotech acquires cell culture specialist Xell AG
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sartorius Stedim Biotech acqui - GuruFocus com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
GÖTTINGEN, Germany, July 21, 2021 /PRNewswire/ The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake
1. In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug devel
Share this article
Share this article
AUBAGNE, France, July 21, 2021 /PRNewswire/ Sartorius Stedim Biotech, a leading partner of the biopharma industry, has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake
1. In the first six months of the year, we have seen unabated high demand for innovative technologies used in the production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug development so
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) .
Basilea Pharmaceutica AGJuly 14, 2021 GMT
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, July 14, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union.
Under the terms of the agreement, JSC Lancet is granted the exclusive right to register, distribute and commercialize Zevtera in the license territory, whilst Basilea will supply JSC Lancet with product at a transfer price. In addition, Basilea will receive an upfront payment and be eligible for sales milestone payments.
vimarsana © 2020. All Rights Reserved.